Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics (Nasdaq: PSTV) announced that its subsidiary CNSide Diagnostics signed a national coverage agreement with Humana effective October 29, 2025, adding coverage for approximately 16 million people and bringing total CNSide CSF TCE LDT policy coverage to 67 million in the U.S.
The CNSide® Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test supports rapid diagnosis, treatment monitoring, and guidance for leptomeningeal metastases. Performance and adoption details: >11,000 tests at >120 U.S. cancer institutions since 2020; 92% sensitivity, 95% specificity; influenced treatment decisions in 90% of cases. The test is available exclusively through CNSide Diagnostics as a U.S. testing service.
Plus Therapeutics (Nasdaq: PSTV) ha annunciato che la sua controllata CNSide Diagnostics ha firmato un accordo nazionale di copertura con Humana, valido dal 29 ottobre 2025, aggiungendo copertura per circa 16 milioni di persone e portando a 67 milioni in USA la copertura totale della politica CNSide CSF TCE LDT.
Il test di laboratorio CNSide® per l enumerazione delle cellule tumorali nel liquido cerebrospinale supporta una diagnosi rapida, monitoraggio del trattamento e guida per le leptomeningeal metastases. Dettagli su prestazioni e adozione: >11.000 test in >120 istituzioni oncologhe statunitensi dal 2020; 92% sensibilità, 95% specificità; ha influenzato le decisioni di trattamento in 90% dei casi. Il test è disponibile esclusivamente tramite CNSide Diagnostics come servizio di testing negli Stati Uniti.
Plus Therapeutics (Nasdaq: PSTV) anunció que su subsidiaria CNSide Diagnostics firmó un acuerdo nacional de cobertura con Humana, vigente desde el 29 de octubre de 2025, añadiendo cobertura para aproximadamente 16 millones de personas y elevando la cobertura total de la póliza CNSide CSF TCE LDT a 67 millones en EE. UU.
La prueba de laboratorio CNSide® para el recuento de células tumorales en el líquido cefalorraquídeo apoya un diagnóstico rápido, monitoreo del tratamiento y orientación para las metástasis leptomeníngeas. Detalles de rendimiento y adopción: >11,000 pruebas en >120 instituciones oncológicas de EE. UU. desde 2020; 92% sensibilidad, 95% especificidad; influyó en decisiones de tratamiento en 90% de los casos. La prueba está disponible exclusivamente a través de CNSide Diagnostics como un servicio de prueba en EE. UU.
Plus Therapeutics (Nasdaq: PSTV) 은 자회사 CNSide Diagnostics 가 Humana 와 전국 커버리지 계약을 체결했다고 발표했습니다. 발효일은 2025년 10월 29일, 약 1,600만명의 커버리지를 추가하고 미국 내 CNSide CSF TCE LDT 정책 커버리지를 총 6700만으로 확대합니다.
CNSide® 척수액 종양세포 수 측정 실험실개발검사는 빠른 진단, 치료 모니터링, 그리고 leptomeningeal metastases에 대한 안내를 지원합니다. 성능 및 채택 세부정보: 2020년 이래로 11,000건 이상의 검사, 120개 이상의 미국 암기관에서 실시; 민감도 92%, 특이도 95%; 치료 의사결정에 영향을 미친 사례 90%. 이 검사는 미국 내 CNSide Diagnostics 를 통해서만 테스트 서비스로 제공됩니다.
Plus Therapeutics (Nasdaq: PSTV) a annoncé que sa filiale CNSide Diagnostics a signé un accord national de couverture avec Humana, effectif à partir du 29 octobre 2025, ajoutant une couverture pour environ 16 millions de personnes et portant la couverture totale de la politique CNSide CSF TCE LDT à 67 millions aux États-Unis.
Le test de laboratoire CNSide® d’énumération des cellules tumorales du liquide céphalo-rachidien (LCR) soutient un diagnostic rapide, le suivi du traitement et l’orientation pour les métastases leptomeningées. Détails sur la performance et l’adoption : >11 000 tests dans >120 institutions cancer américaines depuis 2020 ; 92% de sensibilité, 95% de spécificité ; a influencé les décisions de traitement dans 90% des cas. Le test est disponible exclusivement via CNSide Diagnostics en tant que service de test aux États‑Unis.
Plus Therapeutics (Nasdaq: PSTV) hat bekannt gegeben, dass seine Tochtergesellschaft CNSide Diagnostics eine nationale Abdeckungvereinbarung mit Humana abgeschlossen hat, gültig ab dem 29. Oktober 2025, wodurch eine Abdeckung für ca. 16 Millionen Menschen hinzukommt und die gesamte CNSide CSF TCE LDT-Policy-Abdeckung in den USA auf 67 Millionen erhöht wird.
Der CNSide® Labor entwickelte Test zur Enumeration von Tumorzellen im Liquor cerebrospinalis unterstützt eine schnelle Diagnose, Therapiekontrolle und Orientierung für leptomeningeale Metastasen. Leistungs- und Übernahme-Details: >11.000 Tests in >120 US-Krebsinstitutionen seit 2020; 92% Empfindlichkeit, 95% Spezifität; beeinflusste Behandlungsentscheidungen in 90% der Fälle. Der Test ist ausschließlich über CNSide Diagnostics als US-Testdienst erhältlich.
Plus Therapeutics (Nasdaq: PSTV) أعلنت أن شركتها التابعة CNSide Diagnostics وقعت اتفاقية تغطية وطنية مع Humana سارية اعتباراً من 29 أكتوبر 2025، مضيفة تغطية لحوالي 16 مليون شخص ورفع إجمالي تغطية سياسة CNSide CSF TCE LDT في الولايات المتحدة إلى 67 مليون.
اختبار CNSide® المختبري لعدّ خلايا الورم في السائل النخاعي الدماغي يدعم التشخيص السريع، ومراقبة العلاج، وتوجيه لعلاج النقائل العنكبية leptomeningeal metastases. تفاصيل الأداء والتبني: أكثر من 11,000 اختبار في أكثر من 120 مؤسسة سرطانية أمريكية منذ 2020; حساسية 92%, خصوصية 95%; وقد أثر في قرارات العلاج في 90% من الحالات. الاختبار متاح حصرياً من خلال CNSide Diagnostics كخدمة فحص في الولايات المتحدة.
- Coverage added for ~16 million people (Humana agreement)
- Total policy coverage increased to 67 million
- >11,000 CNSide tests performed since 2020
- Test performance: 92% sensitivity, 95% specificity
- None.
HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Humana, Inc. (NYSE: HUM), effective October 29, 2025, covering approximately 16 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) laboratory developed test (LDT). This brings CNSide CSF TCE LDT total policy coverage to 67 million people.
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com.
About Humana
Humana Inc. (NYSE: HUM) is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
investor@plustherapeutics.com
FAQ
What did Plus Therapeutics announce about Humana coverage for PSTV on November 20, 2025?
How many people does the CNSide CSF TCE LDT now cover for PSTV?
What are the clinical performance metrics for the CNSide CSF assay (PSTV)?
How widely has the CNSide CSF test been used since 2020 for PSTV?
What clinical utility evidence supports the CNSide CSF assay for PSTV?
